PPARA and type 2 diabetes mellitus: The PPARs have already yielded viable targets for the treatment of T2DM and dyslipidemia; thiazolidinediones, PPARγ agonists, are currently used in the clinic for the treatment of T2DM; and fibrates, PPARα agonists, are routinely used to treat dyslipidemia.